drugset / Trial / NCT07372807

Ripertamab for the Treatment of Myasthenia Gravis

NCT07372807

Phase 1/2 Not yet recruiting 20 enrolled Zhongming Qiu
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if ripertamab works to treat myasthenia gravis. It will also learn about the safety of ripertamab. The main questions it aims to answer are:Will ripertamab improve the symptoms of participants?What medical problems do participants have when using ripertamab?Researchers will compare ripertamab to a placebo (a look-alike substance that contains no drug) to see if ripertamab works to treat chronic inflammatory demyelinating polyneuropathy.Participants will:A single intravenous infusion of ripertamab.Visit the clinic for checkups and tests during W1, W2, W4, W8, W12. Keep a diary of their symptoms and the number of times they undergo rescue therapy.

Timeline

Start
2026-02
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ripertamab Monoclonal antibody 375 mg/m2 Intravenous

Indications